FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma

Journal of Clinical Oncology

Volumn 29, Issue 29, 2011, Pages 3852-3861

  Remke, Marc ^a,b   Hielscher, Thomas ^a   Korshunov, Andrey ^a,b   Northcott, Paul A ^e   Bender, Sebastian ^a,b   Kool, Marcel ^f   Westermann, Frank ^a   Benner, Axel ^a   Cin, Huriye ^a   Ryzhova, Marina ^g   Sturm, Dominik ^a   Witt, Hendrik ^a,b   Haag, Daniel ^a   Toedt, Grischa ^a   Wittmann, Andrea ^a   Schöttler, Anna ^a   Von Bueren, André O ^c   Von Deimling, Andreas ^a,b   Rutkowski, Stefan ^c   Scheurlen, Wolfram ^d   Kulozik, Andreas E ^b   Taylor, Michael D ^e   Lichter, Peter ^b   Pfister, Stefan M ^a,b   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Cnopf'Sche Kinderklinik Nü Rnberg Children's Hospital   (Germany)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLISTATIN LIKE 5 PROTEIN; FOLLISTATIN RELATED PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; WNT1 PROTEIN;

ARTICLE; BIOINFORMATICS; CANCER DIAGNOSIS; CANCER RELAPSE; COHORT ANALYSIS; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MALE; MEDULLOBLASTOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY;

BRAIN NEOPLASMS; CHILD; COHORT STUDIES; DISEASE-FREE SURVIVAL; FOLLISTATIN-RELATED PROTEINS; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; MEDULLOBLASTOMA; MICROARRAY ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053980912     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.2798     Document Type: Article

References (36)

1. Polkinghorn WR, Tarbell NJ: Medulloblastoma: Tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4:295-304, 2007 (Pubitemid 46758787)
2. Korshunov A, Remke M, Werft W, et al: Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 28:3054-3060, 2010
3. Pfister S, Remke M, Benner A, et al: Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27:1627-1636, 2009
4. Scheurlen WG, Schwabe GC, Joos S, et al: Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 16:2478-2485, 1998 (Pubitemid 28309044)
5. Clifford SC, Lusher ME, Lindsey JC, et al: Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 5:2666-2670, 2006
6. Ellison DW, Onilude OE, Lindsey JC, et al: beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23:7951-7957, 2005 (Pubitemid 46657395)
7. Gajjar A, Hernan R, Kocak M, et al: Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22:984-993, 2004 (Pubitemid 41095029)
8. Gilbertson R, Wickramasinghe C, Hernan R, et al: Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85:705-712, 2001 (Pubitemid 32929469)
9. Grotzer MA, Hogarty MD, Janss AJ, et al: MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 7:2425-2433, 2001 (Pubitemid 32751645)
10. Pan E, Pellarin M, Holmes E, et al: Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 11:4733-4740, 2005 (Pubitemid 41557192)
11. Northcott PA, Korshunov A, Witt H, et al: Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29:1408-1414, 2011
12. Kool M, Koster J, Bunt J, et al: Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3:e3088, 2008
13. Thompson MC, Fuller C, Hogg TL, et al: Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24:1924-1931, 2006
14. Pizer BL, Clifford SC: The potential impact of tumour biology on improved clinical practice for medulloblastoma: Progress towards biologically driven clinical trials. Br J Neurosurg 23:364-375, 2009
15. Romer JT, Kimura H, Magdaleno S, et al: Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 6:229-240, 2004 (Pubitemid 39222036)
16. Rudin CM, Hann CL, Laterra J, et al: Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361:1173-1178, 2009
17. Kortmann RD, Kühl J, Timmermann B, et al: Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46:269-279, 2000 (Pubitemid 30067775)
18. von Hoff K, Hinkes B, Gerber NU, et al: Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. Eur J Cancer 45:1209-1217, 2009
19. Northcott PA, Fernandez-L A, Hagan JP, et al: The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 69:3249-3255, 2009
20. Northcott PA, Nakahara Y, Wu X, et al: Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41:465-472, 2009
21. Rasheed BK, Wiltshire RN, Bigner SH, et al: Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 11:162-167, 1999 (Pubitemid 29229607)
22. Remke M, Hielscher T, Northcott PA, et al: Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 29:2717-2723, 2011
23. Traenka C, Remke M, Korshunov A, et al: Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. Cancer Res 70:8003-8014, 2010
24. Troyanskaya O, Cantor M, Sherlock G, et al: Missing value estimation methods for DNA microarrays. Bioinformatics 17:520-525, 2001 (Pubitemid 32600498)
25. Suzuki R, Shimodaira H: Pvclust: An R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22:1540-1542, 2006 (Pubitemid 43985330)
26. Goeman JJ, van de Geer SA, de Kort F, et al: A global test for groups of genes: Testing association with a clinical outcome. Bioinformatics 20:93-99, 2004 (Pubitemid 38088346)
27. Lausen B, Hothorn T, Bretz F, et al: Assessment of optimal selected prognostic factors. Biometrical Journal 46:364-374, 2004 (Pubitemid 41449114)
28. Firth D: Bias reduction of maximum likelihood estimates. Biometrika 80:27-38, 1993
29. Graf E, Schmoor C, Sauerbrei W, et al: Assessment and comparison of prognostic classification schemes for survival data. Stat Med 18:2529-2545, 1999 (Pubitemid 29423514)
30. Brunet JP, Tamayo P, Golub TR, et al: Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A 101:4164-4169, 2004 (Pubitemid 38405900)
31. Cho YJ, Tsherniak A, Tamayo P, et al: Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29:1424-1430, 2011
32. Schwalbe EC, Lindsey JC, Straughton D, et al: Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res 17:1883-1894, 2011
33. Masuda T, Kai N, Sakuma C, et al: Laser capture microdissection and cDNA array analysis for identification of mouse KIAA/FLJ genes differentially expressed in the embryonic dorsal spinal cord. Brain Res 1249:61-67, 2009
34. Grusch M, Drucker C, Peter-Vörösmarty B, et al: Deregulation of the activin/follistatin system in hepatocarcinogenesis. J Hepatol 45:673-680, 2006 (Pubitemid 44466665)
35. Trojan L, Schaaf A, Steidler A, et al: Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res 25:183-191, 2005 (Pubitemid 40470109)
36. Reddy SP, Britto R, Vinnakota K, et al: Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis. Clin Cancer Res 14:2978-2987, 2008